The Diabetes Forum Support Community For Diabetics Online banner

1 - 1 of 1 Posts

·
Registered
Joined
·
1,288 Posts
Discussion Starter · #1 ·
Comparing Insulin Degludec And Insulin Glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia - low blood sugar - compared with the commercially available insulin glargine, a new meta-analysis study finds. Results of the combined analysis, of five completed clinical trials, were presented at The Endocrine Society's 95th Annual Meeting in San Francisco.

The studies included nearly 3,400 adults with type 2 diabetes who had a daily injection of either insulin degludec or glargine combined with either a mealtime insulin or oral diabetic medications.

"Compared with insulin glargine, insulin degludec may offer considerable benefits by reducing the major side effect of insulin therapy, hypoglycemia," said the study's principal investigator, Alan Garber, MD, PhD, professor of medicine, biochemistry and molecular biology, and molecular and cellular biology at Baylor College of Medicine, Houston.
 
1 - 1 of 1 Posts
Top